Article Type
Changed
Display Headline
Systemic Sclerosis Patients May Need Higher Doses of Vit. D

SAN FRANCISCO — A study of 156 patients with systemic sclerosis in two European cities found that vitamin D deficiency was common, present in 28%.

Deficient levels of serum 25-hydroxyvitamin D (25[OH]D)—less than 10 ng/mL—were seen in 29 (32%) of 90 patients in Paris and 15 (23%) of 66 in southern Italy, Dr. Alessandra Vacca and her associates reported in a poster presentation at the annual meeting of the American College of Rheumatology. In addition, 84% of all patients had insufficient vitamin D levels (less than 30 ng/mL), seen in 75 (82%) of the Parisians and 57 (86%) of the Italians.

Overall, patients had a mean age of 57 years, and 97% were female. The mean vitamin D value in the two cohorts was 19 ng/mL, said Dr. Vacca of the University of Cagliari.

The rates of vitamin D deficiency did not differ significantly between cities and so were independent of the different UV radiation levels in the northern and southern cities. Rates of vitamin D deficiency also were independent of usual levels of vitamin D supplementation (800 IU/day), taken by 30% of Parisian patients and 45% of Italian patients.

Because conventional doses of vitamin D supplementation did not prevent vitamin D deficiency, higher-dose supplementation may be needed in patients with systemic sclerosis, especially those with inflammatory activity, she said.

Low vitamin D levels were associated with pulmonary fibrosis (P = .04), systolic pulmonary arterial hypertension (P = .004), and inflammatory activity indicated by acute phase reactants—erythrocyte sedimentation rate (P = .004) and C-reactive protein values (P = .01). There was a significant negative correlation between low vitamin D levels and European disease activity scores (P = −0.04). A mild negative association was seen between vitamin D deficiency and anticentromere antibodies.

Low vitamin D levels may be linked to multiple risk factors, Dr. Vacca suggested, including scarce sun exposure due to disability, insufficient intake and malabsorption of vitamin D due to gastroenteric involvement, or use of drugs that can alter metabolism of vitamin D. There was no association between vitamin D deficiency and other markers of impaired malabsorption such as hemoglobin, ferritin, or albuminemia. No associations were found between vitamin D deficiency and acro-osteolysis, calcinosis, or Medsger's disease severity score.

The investigators reported no conflicts of interest related to this study.

Article PDF
Author and Disclosure Information

Publications
Topics
Author and Disclosure Information

Author and Disclosure Information

Article PDF
Article PDF

SAN FRANCISCO — A study of 156 patients with systemic sclerosis in two European cities found that vitamin D deficiency was common, present in 28%.

Deficient levels of serum 25-hydroxyvitamin D (25[OH]D)—less than 10 ng/mL—were seen in 29 (32%) of 90 patients in Paris and 15 (23%) of 66 in southern Italy, Dr. Alessandra Vacca and her associates reported in a poster presentation at the annual meeting of the American College of Rheumatology. In addition, 84% of all patients had insufficient vitamin D levels (less than 30 ng/mL), seen in 75 (82%) of the Parisians and 57 (86%) of the Italians.

Overall, patients had a mean age of 57 years, and 97% were female. The mean vitamin D value in the two cohorts was 19 ng/mL, said Dr. Vacca of the University of Cagliari.

The rates of vitamin D deficiency did not differ significantly between cities and so were independent of the different UV radiation levels in the northern and southern cities. Rates of vitamin D deficiency also were independent of usual levels of vitamin D supplementation (800 IU/day), taken by 30% of Parisian patients and 45% of Italian patients.

Because conventional doses of vitamin D supplementation did not prevent vitamin D deficiency, higher-dose supplementation may be needed in patients with systemic sclerosis, especially those with inflammatory activity, she said.

Low vitamin D levels were associated with pulmonary fibrosis (P = .04), systolic pulmonary arterial hypertension (P = .004), and inflammatory activity indicated by acute phase reactants—erythrocyte sedimentation rate (P = .004) and C-reactive protein values (P = .01). There was a significant negative correlation between low vitamin D levels and European disease activity scores (P = −0.04). A mild negative association was seen between vitamin D deficiency and anticentromere antibodies.

Low vitamin D levels may be linked to multiple risk factors, Dr. Vacca suggested, including scarce sun exposure due to disability, insufficient intake and malabsorption of vitamin D due to gastroenteric involvement, or use of drugs that can alter metabolism of vitamin D. There was no association between vitamin D deficiency and other markers of impaired malabsorption such as hemoglobin, ferritin, or albuminemia. No associations were found between vitamin D deficiency and acro-osteolysis, calcinosis, or Medsger's disease severity score.

The investigators reported no conflicts of interest related to this study.

SAN FRANCISCO — A study of 156 patients with systemic sclerosis in two European cities found that vitamin D deficiency was common, present in 28%.

Deficient levels of serum 25-hydroxyvitamin D (25[OH]D)—less than 10 ng/mL—were seen in 29 (32%) of 90 patients in Paris and 15 (23%) of 66 in southern Italy, Dr. Alessandra Vacca and her associates reported in a poster presentation at the annual meeting of the American College of Rheumatology. In addition, 84% of all patients had insufficient vitamin D levels (less than 30 ng/mL), seen in 75 (82%) of the Parisians and 57 (86%) of the Italians.

Overall, patients had a mean age of 57 years, and 97% were female. The mean vitamin D value in the two cohorts was 19 ng/mL, said Dr. Vacca of the University of Cagliari.

The rates of vitamin D deficiency did not differ significantly between cities and so were independent of the different UV radiation levels in the northern and southern cities. Rates of vitamin D deficiency also were independent of usual levels of vitamin D supplementation (800 IU/day), taken by 30% of Parisian patients and 45% of Italian patients.

Because conventional doses of vitamin D supplementation did not prevent vitamin D deficiency, higher-dose supplementation may be needed in patients with systemic sclerosis, especially those with inflammatory activity, she said.

Low vitamin D levels were associated with pulmonary fibrosis (P = .04), systolic pulmonary arterial hypertension (P = .004), and inflammatory activity indicated by acute phase reactants—erythrocyte sedimentation rate (P = .004) and C-reactive protein values (P = .01). There was a significant negative correlation between low vitamin D levels and European disease activity scores (P = −0.04). A mild negative association was seen between vitamin D deficiency and anticentromere antibodies.

Low vitamin D levels may be linked to multiple risk factors, Dr. Vacca suggested, including scarce sun exposure due to disability, insufficient intake and malabsorption of vitamin D due to gastroenteric involvement, or use of drugs that can alter metabolism of vitamin D. There was no association between vitamin D deficiency and other markers of impaired malabsorption such as hemoglobin, ferritin, or albuminemia. No associations were found between vitamin D deficiency and acro-osteolysis, calcinosis, or Medsger's disease severity score.

The investigators reported no conflicts of interest related to this study.

Publications
Publications
Topics
Article Type
Display Headline
Systemic Sclerosis Patients May Need Higher Doses of Vit. D
Display Headline
Systemic Sclerosis Patients May Need Higher Doses of Vit. D
Article Source

PURLs Copyright

Inside the Article

Article PDF Media